Werkgroep Cardiologische centra Nederland

OCEAN(a) Outcomes (Follow-up)

A Double-blind, Randomized, Placebo-controlled, Multicenter Study Assessing the Impact of Olpasiran on Major Cardiovascular Events in Patients with Atherosclerotic Cardiovascular Disease and Elevated Lipoprotein (a)
Medicine
Olpasiran
Population
ASCVD
Phase
III
Starting year
2022

Director of Study

dr. J. Schaap (Cardioloog)
Breda, Amphia Ziekenhuis